Navigation Links
Anti-anginal Drug Not Effective in Reducing Major Cardiac Events

Despite being safe, anti-anginal medication Ranolazine has not been effective in reducing the risk of major cardiovascular events such as death// , heart attack or recurrent ischemia following acute coronary syndromes.

Despite advances in the treatment of acute coronary syndromes (ACS), the risk of recurrent events remains substantial. The medication ranolazine is used for patients with chronic angina, but because of an association between ranolazine and prolongation of the QT interval (a certain measurement on an electrocardiogram), there is a need for additional safety information to guide its use in patients with coronary artery disease. The effectiveness and safety of the drug had not previously been studied in patients with ACS or for secondary prevention of major cardiovascular events in patients with established coronary artery disease, according to background information in the article.

David A. Morrow, M.D., M.P.H., of Brigham and Women's Hospital and Harvard Medical School, Boston, and colleagues with the MERLIN (Metabolic Efficiency With Ranolazine for Less Ischemia in Non−ST-Elevation Acute Coronary Syndromes)-TIMI 36 trial evaluated the efficacy and safety of ranolazine as a new treatment to reduce cardiovascular death, heart attack or recurrent ischemia in moderate- to high-risk patients with non–ST-elevation (a certain pattern on an electrocardiogram) ACS. The randomized, multinational clinical trial included 6,560 patients who within 48 hours of ischemic symptoms were treated with ranolazine (initiated intravenously and followed by oral ranolazine extended-release 1,000 mg twice daily, n = 3,279) or matching placebo (n = 3,281), and followed up for a midpoint of 348 days.

The primary end point (cardiovascular death, heart attack, or recurrent ischemia) occurred in 21.8 percent of the patients in the ranolazine group, compared with 23.5 percent of the patients in the placebo group. The major secondary end poin t (cardiovascular death, heart attack, or severe recurrent ischemia) occurred in 18.7 percent of the patients in the ranolazine group compared with 19.2 percent of the patients in the placebo group. Failure of therapy (including cardiovascular death, heart attack, recurrent ischemia, hospitalization for new or worsening heart failure) occurred at similar rates in both groups. The risk of recurrent ischemia was reduced in the ranolazine group (13.9 percent) compared with the placebo group (16.1 percent). Symptomatic documented arrhythmias did not differ between the two groups. There was little difference in the total number of deaths between the ranolazine and placebo groups (172 vs. 175, respectively).

"The results of this robustly powered, randomized trial do not support the use of ranolazine for acute management of ACS or as disease-modifying therapy for secondary prevention of cardiovascular death or [heart attack]. However, our findings suggest a benefit of ranolazine as antianginal therapy in a substantially more broad population of patients with established ischemic heart disease than previously studied," the authors write. "These findings, together with the observed favorable overall profile of safety, provide additional evidence to guide the use of ranolazine as antianginal therapy in patients with chronic angina."

Source-Eurekalert
'"/>




Related medicine news :

1. New Way to "See" Genes, Evaluate Effectiveness of Gene Therapies Discovered
2. Inhaled Steroids Safe & Effective for Children with Asthma
3. ZD1839 Proves Effective - A Breakthrough in fighting Lung Cancer
4. Fluoride Found Effective in Osteoporosis
5. Aspirin and Warfarin Are Equally Effective for Stroke Prevention
6. Implantable Contact Lens Found Safe and Effective
7. Effective And Economical Agent For Anthrax
8. Stem Cell Transplants May Be Effective For MS Patients
9. Effective therapy for Huntingtons disease
10. Chemotherapy Effective for Bladder Cancer
11. Drug Effective for Vascular Dementia
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/26/2016)... ... , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect ... a whole new perspective by using the title layers in ProSlice Levels to ... ProSlice Levels contains over 30 Different presets to choose from. FCPX users ...
(Date:6/25/2016)... D.C. (PRWEB) , ... June 25, 2016 , ... ... discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, ... their work on several important health care topics including advance care planning, healthcare ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the ... Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , “We ... new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Any dentist who has made ... the current process. Many of them do not even offer ... difficulties and high laboratory costs involved. And those who ARE ... at such a high cost that the majority of today,s ... Dr. Parsa Zadeh , founder of Dental Evolutions Inc. ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... to 2022" report to their offering. ... financial data derived from varied research sources to present unique ... on the market during the next five years, including a ... markets, regional and country level analysis. The report provides a ...
(Date:6/23/2016)... MOUNTAIN VIEW, Calif. , June 23, 2016 ... 9:00 a.m. CST on Thursday, July 7, 2016 , , ... kayla.belcher@frost.com ) , , , , EXPERT PANELISTS:  ... Sciences, Nitin Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, ... The global pharmaceutical industry is witnessing ...
Breaking Medicine Technology: